Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) Price Target at $6.00
by Danessa Lincoln · The Markets DailyTScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report) has received a consensus recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $6.00.
TCRX has been the topic of several analyst reports. Wedbush upped their target price on TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of TScan Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th.
Check Out Our Latest Stock Analysis on TScan Therapeutics
Insider Transactions at TScan Therapeutics
In other news, major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of the business’s stock in a transaction on Friday, December 19th. The shares were acquired at an average price of $0.90 per share, with a total value of $72,062.10. Following the completion of the transaction, the insider owned 7,937,416 shares of the company’s stock, valued at $7,143,674.40. The trade was a 1.02% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 161,801 shares of company stock valued at $145,621 in the last quarter. 4.35% of the stock is owned by insiders.
Institutional Investors Weigh In On TScan Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the business. Catalyst Funds Management Pty Ltd bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $26,000. Quadrature Capital Ltd acquired a new position in shares of TScan Therapeutics during the 2nd quarter valued at $33,000. Boothbay Fund Management LLC boosted its stake in TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after acquiring an additional 8,121 shares in the last quarter. Panagora Asset Management Inc. bought a new position in TScan Therapeutics during the fourth quarter worth $25,000. Finally, HRT Financial LP acquired a new stake in TScan Therapeutics in the fourth quarter worth $26,000. Institutional investors own 82.83% of the company’s stock.
TScan Therapeutics Trading Down 1.8%
TCRX opened at $1.07 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.41 and a quick ratio of 8.41. TScan Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $2.57. The company’s 50 day moving average price is $1.07 and its two-hundred day moving average price is $1.35. The firm has a market capitalization of $60.89 million, a price-to-earnings ratio of -1.07 and a beta of 1.03.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.09. The firm had revenue of $2.57 million during the quarter, compared to the consensus estimate of $2.44 million. TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on equity of 79.36%. As a group, research analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.
About TScan Therapeutics
TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.
The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.